Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.025 USD | +36.78% | -7.22% | -26.44% |
06:02pm | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
12:32pm | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.44% | 113M | |
+3.23% | 108B | |
+10.30% | 105B | |
+1.57% | 23.46B | |
-12.92% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.19% | 17.19B | |
+5.94% | 13.99B | |
+36.84% | 12.53B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024